SELLAS Life Sciences Group, Inc.
SLSSELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel immunotherapies and selective inhibitors for a broad range of cancer indications.
Earnings
Next report
Aug 11, 2026 (In 4 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel immunotherapies and selective inhibitors for a broad range of cancer indications. The company's core value proposition centers on its proprietary peptide immunotherapy platform and next-generation kinase inhibitors designed to target malignancies with high unmet medical needs, particularly in hematologic cancers.
SELLAS is a late-stage clinical developer with Orphan Drug and Fast Track designations for its lead candidates, positioning it as a specialized player in the AML maintenance and CDK9 inhibitor markets.
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s market cap?
- SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $2.7B and trades on NASDAQ.
- Who are SELLAS Life Sciences Group, Inc.'s competitors?
- SELLAS Life Sciences Group, Inc.'s key competitors include AbbVie, Pfizer, AstraZeneca, and others. These companies compete in similar markets and product categories.
- Who does SELLAS Life Sciences Group, Inc. partner with?
- SELLAS Life Sciences Group, Inc.'s notable partners include Memorial Sloan Kettering Cancer Center, 3D Medicines Inc., GenFleet Therapeutics (Shanghai), Inc., and others.
- What subsidiaries does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc.'s subsidiaries include SLSG Limited, LLC.
- Where is SELLAS Life Sciences Group, Inc. headquartered?
- SELLAS Life Sciences Group, Inc. is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2008.